Cardiovascular Risk and Inflammation: Pathophysiological Mechanisms, Drug Design, and Targets

被引：0
|
作者：
Gasparyan, Armen Yuri [1 ]
机构：
[1] Russells Hall Hosp, Dudley Grp NHS Fdn Trust, Dudley DY1 2HQ, W Midlands, England
来源：
CURRENT PHARMACEUTICAL DESIGN | 2012年 / 18卷 / 11期
关键词：
RHEUMATOID-ARTHRITIS; ACCELERATED ATHEROSCLEROSIS; ALPHA THERAPY; DISEASE; ANEURYSMS; STATINS;
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：1447 / 1449
页数：3
相关论文
共 50 条
  • [41] Inflammation, infection, and cardiovascular risk
    Drozd, Michael
    Cubbon, Richard
    LANCET, 2024, 403 (10431): : 1022 - 1023
  • [42] Inflammation as a cardiovascular risk factor
    Willerson, JT
    Ridker, PM
    CIRCULATION, 2004, 109 (21) : 2 - 10
  • [43] Chronic inflammation and cardiovascular risk
    Ker, J. A.
    SOUTH AFRICAN FAMILY PRACTICE, 2010, 52 (01) : 18 - 18
  • [44] Obesity, Inflammation, and Cardiovascular Risk
    Mathieu, P.
    Lemieux, I.
    Despres, J-P
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2010, 87 (04) : 407 - 416
  • [45] Statins, inflammation and cardiovascular risk
    不详
    EXERCER-LA REVUE FRANCOPHONE DE MEDECINE GENERALE, 2023, (197): : 432 - 432
  • [46] Inflammation, Infection, and Cardiovascular risk
    Goldman, Michel
    Bondue, Antoine
    Cogan, Elie
    LANCET, 2024, 403 (10440): : 1021 - 1022
  • [47] Glycosylation targets for drug design
    Hounsell, EF
    CARBOHYDRATE RESEARCH, 1997, 300 (01) : 47 - 48
  • [48] HYDROXYLASES AS TARGETS FOR DRUG DESIGN
    LOVENBERG, W
    ENZYMES AS TARGETS FOR DRUG DESIGN, 1989, : 101 - 119
  • [49] Enzymes as targets for Drug Design
    Palfreyman, M.G.
    Northrop, Dexter B.
    Trends in Biotechnology, 1991, 9 (03):
  • [50] Drug Design of "Undruggable" Targets
    Wang, Jie
    Li, Shiliang
    Li, Honglin
    CHINESE JOURNAL OF CHEMISTRY, 2019, 37 (05) : 501 - 512
12345